



PTO/SB/51 (02-01)

Approved for use through 01/31/2004. OMB 0651-0033
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Project of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Supplemental
REISSUE APPLICATION DECLARATION BY THE INVENTOR

Docket Number (Optional)

54883-USA-REIS

As a below named inventor, I hereby declare that:

My residence, mailing address, and citizenship are stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is described and claimed in patent number 5,597,780, granted January 28, 1997, and for which a reissue patent is sought on the invention entitled Low Volatility Formulations of Clomazone

the specification of which

☐ is attached hereto.

☒ was filed on January 28, 1999 as reissue application number 09 / 239,426
and was amended on January 28, 1999, February 19, 2001 and August 8, 2002
(if applicable)

I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56.

I verily believe the original patent to be wholly or partly inoperative or invalid, for the reasons described below. (Check all boxes that apply.)

☐ by reason of a defective specification or drawing.☒ by reason of the patentee claiming more or less than he had the right to claim in the patent.☐ by reason of other errors.

At least one error upon which reissue is based is described below. If the reissue is a broadening reissue, such must be stated with an explanation as to the nature of the broadening:

Claim 9, step e) as granted requires the microcapsules to have "a suspensibility of greater than 70%", and Applicants believe they are entitled to a broader claim that does not require the microcapsules to have "a suspensibility of greater than 70%".

[Page 1 of 2]

Burden Hour Statement: This form is estimated to take 0.5 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

TECH CENTER 1600/2900

MAY 30 2003

RECEIVED



PTO/SB/S1 (02-01)

Approved for use through 01/31/2004. OMB 0851-0033

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Project 02-235, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

(REISSUE APPLICATION DECLARATION BY THE INVENTOR, page 2)

Docket Number (Optional)

54883-USA-REIS

All errors corrected in this reissue application arose without any deceptive intention on the part of the applicant. As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the United States Patent and Trademark Office connected therewith.

Name(s)	Registration Number
John M. Sheehan	26,065
Marcia D. Pintzuk	33,756
Paul A. Fair	33,866

Correspondence Address: Direct all communications about the application to:

See Attachment

☐ Customer Number

Type Customer Number here

Place Customer Number Bar Code Label here

<input checked="" type="checkbox"/> Firm or Individual Name	Patent Administrator				
Address	1735 Market Street				
Address					
City	Philadelphia	State	PA	Zip	19103
Country	United States of America				
Telephone	(215) 299-6985	Fax	(215) 299-6984		

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine and imprisonment, or both, under 18 U.S.C. 1001, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this declaration is directed.

Full name of sole or first inventor (given name, family name)

Fui-Tseng H. Lee

Inventor's signature

Fui-Tseng H. Lee

Date 5/21/2003

Residence Princeton, NJ

Citizenship U.S. citizen

Mailing Address

38 Wittmer Court, Princeton, NJ 08540

Full name of second joint inventor (given name, family name)

Paul Nicholson

Inventor's signature

Paul Nicholson

Date 5/21/2003

Residence Trenton, NJ

Citizenship U.S. citizen

Mailing Address

615 Greenway Avenue, Trenton, NJ 08618

Full name of third joint inventor (given name, family name)

Inventor's signature

Date

Residence

Citizenship

Mailing Address

☐ Additional joint inventors are named on separately numbered sheets attached hereto.

[Page 2 of 2]

Patent Number: 5,597,780**Issue Date: January 28, 1997****Invention Title: Low Volatility Formulations of Clomazone****Attorney Docket Number: 54883-USA-REIS****Reissue Application Declaration by the Inventor (PTO/SB/51)
Registered Practitioner Information—Supplemental Sheet**

Name	Registration Number	Name	Registration Number
Terence J. Bogie	44,544		
James D. Goodell	33,163		